Director's message: Celebrating a year of research discoveries

Volume 2, Issue 4, 2013

Summary

See highlights from Mayo Clinic Cancer Center's accomplishments in 2013.

Photograph showing Robert B. Diasio, M.D., director, Mayo Clinic Cancer Center

Robert B. Diasio, M.D.

This issue of Forefront marks the end of another busy year at the Mayo Clinic Cancer Center. Here are a few highlights:

  • We celebrated our 40th anniversary as a National Cancer Institute-designated cancer center.
  • We moved closer to our goal of providing proton beam therapy for our patients by completing building construction on our Minnesota facility, which opens in 2015, and steel construction on our Arizona facility, which opens in 2016.
  • We made significant contributions to our understanding of T-cell lymphoma and glioblastoma, identifying biomarkers for each cancer that predict and guide therapy.
  • We definitively showed that calcium and magnesium infusion does not prevent chemotherapy-induced peripheral neuropathy in cancer patients, a practice-changing finding.
  • Our researchers moved closer to developing a DNA stool test that effectively identifies gastrointestinal cancers.
  • We received Food and Drug Administration new drug approval for C11-choline tracer and began using this in imaging tests for recurrent prostate cancer.

These highlights are just a few of the ways we are working to reduce the burden of cancer on patients and their loved ones.

Happy holidays from all of us at the Mayo Clinic Cancer Center. May you enjoy a happy and healthy 2014.

Robert B. Diasio, M.D.
Director, Mayo Clinic Cancer Center
William J. and Charles H. Mayo Professor